CEO John Lechleiter reiterated that Eli Lilly and Co. will not resort to a large-scale merger to counter the
financial impact of patent expiration. "We feel that [with] our current size, with the sizable investment in research and development, we have the way to generate new medicines we need to replace the medicines that we are losing, that are coming off patent in the next several years," he said.

Full Story:

Related Summaries